| Item Type | Name |
|
Concept
|
Lymphatic Metastasis
|
|
Concept
|
Neoplasm Metastasis
|
|
Academic Article
|
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
|
|
Academic Article
|
Prostate cancer metastasis-suppressor genes: a current perspective.
|
|
Academic Article
|
Metastatic bladder cancer: advances in treatment.
|
|
Academic Article
|
A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
|
|
Academic Article
|
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
|
|
Academic Article
|
Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential.
|
|
Academic Article
|
Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases.
|
|
Academic Article
|
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
|
|
Academic Article
|
Gemcitabine doublets in advanced urothelial cancer.
|
|
Academic Article
|
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity.
|
|
Academic Article
|
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
|
|
Academic Article
|
Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
|
|
Academic Article
|
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
|
|
Academic Article
|
Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells.
|
|
Academic Article
|
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
|
|
Academic Article
|
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
|
|
Academic Article
|
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
|
|
Academic Article
|
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
|
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
|
Academic Article
|
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.
|
|
Academic Article
|
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
|
Academic Article
|
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.
|
|
Academic Article
|
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
|
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
|
Academic Article
|
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
|
|
Academic Article
|
Adjuvant chemotherapy in lymph node positive bladder cancer.
|
|
Academic Article
|
Effective therapy for metastatic renal cancer, whither to now.
|
|
Academic Article
|
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
|
|
Academic Article
|
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
|
|
Academic Article
|
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
|
|
Academic Article
|
Dynamic contrast-enhanced MR imaging findings of bone metastasis in patients with prostate cancer.
|
|
Academic Article
|
Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.
|
|
Academic Article
|
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Prognosis and prediction in a Facebook world.
|
|
Academic Article
|
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
|
|
Academic Article
|
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Low-grade prostate cancer diverges early from high grade and metastatic disease.
|
|
Academic Article
|
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
|
|
Academic Article
|
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
|
|
Academic Article
|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
|
|
Academic Article
|
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial.
|
|
Academic Article
|
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
|
|
Academic Article
|
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
|
|
Academic Article
|
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
|
|
Academic Article
|
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
|
|
Academic Article
|
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
|
|
Academic Article
|
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
|
|
Academic Article
|
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
|
|
Academic Article
|
Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.
|
|
Academic Article
|
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
|
|
Academic Article
|
Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.
|
|
Academic Article
|
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
|
|
Academic Article
|
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case.
|